摘要
α受体介导的前列腺尿道平滑肌张力增加是BPH相关性尿道梗阻的动力学因素,α_1受体阻断剂是目前BPH内科治疗的首选药。寻求对泌尿道有高选择性α-(1A)受体阻断剂是今后药物研制的发展方向。
a adrenoceptor-mediated increases in smooth muscle tone of the prostate gland and urethra acts as a dynamic factor for BPH-related obstruction of the urethra, a1 adrenoceptor antagonists are considered as the first-line therapy for the patients with BPH. The search for selective a1A a-drenoceptor antogonists with high uroselectivity is strategical for drug discovery research.
出处
《中国药理学通报》
CAS
CSCD
北大核心
1998年第S1期76-79,共4页
Chinese Pharmacological Bulletin
基金
河北省博士后基金资助
No 96-118
关键词
良性前列腺增生症
药物治疗
Α受体阻断剂
尿道选择性
BPH ( benign prostatic hyperplasia)
medicine treatment
a adrenoceptor antogomsts
uroselectivity
